Agilent Technologies Expands Dako's CE Marked PD-l1 IHC 22C3 PharmDx Companion Diagnostics

Patients with PD-L1-positive unresectable, advanced or recurrent NSCLC can now be identified for treatment with KEYTRUDA (pembrolizumab) using PD-L1 IHC 22C3 pharmDx.

Agilent Technologies ‘ CE marked Dako PD-L1IHC 22C3 pharmDx can now be used to determine PD-L1 expression status to inform the first-line treatment of metastatic non-small cell lung cancer (NSCLC) patients with KEYTRUDA (pembrolizumab), an anti-PD-1 therapy manufactured by Merck or MSD as it is known outside the US and Canada. This intended use allows PD-L1 IHC 22C3 pharmDx to detect PD-L1 expression in both untreated and previously treated metastatic NSCLC patients. KEYTRUDA is now approved for the first-line treatment of metastatic NSCLC patients whose tumours express high levels of PD-L1 (tumour proportion score of 50 per cent or more) or for previously treated metastatic NSCLC patients whose tumours express PD-L1 (tumour proportion score of one per cent or more).